Review
T-Cell Acute Lymphoblastic Leukemia—Current Concepts in Molecular Biology and Management

Parveen Shiraz 1,*, Waqas Jehangir 2 and Vaibhav Agrawal 3

1 Blood and Marrow Transplantation/Cell Therapy, Stanford University, Stanford, CA 94305, USA
2 Avera Medical Group Hematology, Transplant & Cellular Therapy, Sioux Falls, SD 57105, USA; waqas.jehangir@avera.org
3 Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA; vagrawal@coh.org
* Correspondence: pshiraz@stanford.edu

Abstract: T-cell acute lymphoblastic leukemia (T-ALL) is an uncommon, yet aggressive leukemia that accounts for approximately one-fourth of acute lymphoblastic leukemia (ALL) cases. CDKN2A/CDKN2B and NOTCH1 are the most common mutated genes in T-ALL. Children and young adults are treated with pediatric intensive regimens and have superior outcomes compared to older adults. In children and young adults, Nelarabine added to frontline chemotherapy improves outcomes and end of consolidation measurable residual disease has emerged as the most valuable prognostic marker. While outcomes for de-novo disease are steadily improving, patients with relapsed and refractory T-ALL fare poorly. Newer targeted therapies are being studied in large clinical trials and have the potential to further improve outcomes. The role of allogeneic stem cell transplant (HSCT) is evolving due to the increased use of pediatric-inspired regimens and MRD monitoring. In this review we will discuss the biology, treatment, and outcomes in pediatric and adult T-ALL.

Keywords: acute lymphoblastic leukemia; T-cell leukemia; NOTCH; Nelarabine

1. Introduction

Children, adolescents, and young adults comprise 70% of ALL cases [1]. The incidence of ALL in United States (US) is 1.8 per 100,000 for all age groups and 5 per 100,000 for ages 0–19 [1]. While the incidence in Europe is comparable to the US, data suggest higher incidence in Mexico and other Latin American countries [2–4]. Survival in ALL is strongly influenced by age with five-year overall survival being 80% in <50 years and <35% in >50 years [1]. T-ALL comprises 15–25% of ALL cases in children and adults [5–9]. Therefore, T-ALL is primarily a disease of children and young adults and rare in older adults. Sequential accumulation of genomic lesions in the immature T cell progenitors culminates in leukemic transformation and a high proliferative index translates clinically to leukocytosis and extramedullary disease, including large mediastinal/thymic masses and central nervous system (CNS) involvement. The genomic and molecular aberrations seen in T-ALL are distinct from that of B-ALL, yet, up until recently, similar treatment regimens were used for both diseases. The distinction between T-ALL and T-lymphoblastic lymphoma (T-LBL) depends on the degree of bone marrow involvement, with T-ALL cases defined by 20% or more blasts in the bone marrow, whereas T-LBL cases have less than 20% bone marrow blasts with predominance of extramedullary disease [10]. This review will be limited to T-ALL. Early T precursor cell ALL (ETP-ALL) is a distinct subtype arising from immature T-cells and will be discussed in detail. As with B-ALL, outcomes in all age groups, especially for children and young adults, have improved over the past several decades [11,12].
2. Genomics and Molecular Biology

We will begin this section with a discussion of normal thymocyte development, including the role of NOTCH and MYC, followed by a description of the genomic landscape of T-ALL.

2.1. Thymocyte Development

Thymocyte development in mice has been extensively studied using in vivo and in vitro models [13]. Uncommitted lymphoid cells from the bone marrow proliferate when stimulated by Interleukin-7 (IL-7) and stem cell factor (SCF) upon entering the thymus [14,15]. These cells express the NOTCH1 receptor and are activated by NOTCH ligands termed “delta-like” and “Jagged”, which are expressed by the thymic epithelial cells [14,16]. NOTCH activation is required to transform lymphoid precursor cells to T-cells and in the absence of NOTCH, these precursor lymphoid cells by default become B cells [17]. It is important to note that these lymphoid precursor cells retain NK and myeloid markers. Early thymocytes that lack surface CD4 and CD8, called double negative (DN) cells, progress through four stages of differentiation labeled DN1, DN2, DN3, and DN4. DN3 cells exhibit pre-TCR (T-cell receptor) composed of pre-Tα and a rearranged TCRβ chain. DN3 cells have high levels of NOTCH signaling [18], which induces marked cell proliferation as they become DN4 cells. Only those DN cells that have successfully rearranged TCRβ chain transform to double positive (DP) cells expressing CD4 and CD8, at which point they cease to proliferate and undergo rearrangement of the TCRα chain to form a complete TCR that can recognize MHC (major histocompatibility complex). Only those DP cells that are capable of recognizing MHC survive (positive selection) and become single positive CD4 or CD8 cells. These single positive CD4 and CD8 cells then face MHC with self-antigens and only those that do not exhibit a strong response to self-antigens survive (negative selection). Positive and negative selection eliminate the majority of thymocytes, leaving behind mature T cells capable of recognizing foreign antigens and tolerant of self-antigens [14].

2.2. NOTCH and MYC

NOTCH1 is a transmembrane receptor protein that serves as a transcription factor [14,16]. Once activated by delta-like and Jagged ligands, the intracellular portion is cleaved by gamma secretase, translocates to the nucleus, and activates expression of target genes [14,16,19,20]. FBXW7 directs the intracellular portion of NOTCH1 for degradation, thus terminating NOTCH signaling [14,19,21]. Activating mutations of the NOTCH gene or loss of function mutations of the FBXW7 gene lead to constitutive NOTCH signaling in T-ALL [22,23]. Therapeutic inhibition of this pathway has been studied with NOTCH antibodies and gamma secretase inhibitors, albeit with little success [24,25].

The MYC oncogene encodes for transcription factors that regulate genes involved in cell cycle progression, ribosome synthesis, protein translation, and metabolism [26]. MYC plays an important role in the self-renewal and differentiation of hematopoietic stem cells [27] as well as in the development of B and T lymphocytes [28,29]. Deregulated MYC signaling has been implicated in several tumor types including B and T cell malignancies [30,31]. MYC expression is increased in the developing thymic precursor T cells and loss of MYC is associated with severely decreased numbers of thymocytes [14,32]. Several preclinical studies of T-ALL have demonstrated high levels of MYC expression, which is required for the growth and proliferation of leukemic T-cells [14,33–35]. MYC is shown to be downstream of NOTCH1 in the signaling cascade [33]. NOTCH1 mutations are associated with increased level of MYC RNA and conversely NOTCH1 inhibition decreases MYC RNA levels [14]. Additionally, retroviral expression of MYC has been shown to rescue leukemic cells from growth arrest induced by NOTCH1 or gamma secretase inhibitors [36]. NOTCH1 activates MYC expression via the DNA enhancer sequence NMe (NOTCH MYC enhancer) [34]. Enhancer sequences when bound by transcription factors increase the transcription of an associated gene. NMe is occupied by NOTCH1 and directly
interacts with the MYC promoter and induces MYC expression in developing thymocytes and T-ALL cells [34]. NMe knockout mice demonstrate severely decreased thymic cellularity with reductions in immature and mature T cells [34]. In addition, isogenic immune deficient mice fail to develop T-ALL when transplanted with NMe knockout hematopoietic progenitors with retrovirally driven constitutive activation of NOTCH1 [34]. In addition, NMe deletion after leukemia induction resulted in antileukemic effects and improved survival [34]. Proteosomal degradation of MYC protein which has a short half-life, is mediated by FBXW7 [35]. Therefore, T-ALL cases with FBXW7 mutations have increased levels of MYC protein [14,35].

2.3. Genomic Landscape of T-ALL

T-ALL arises from maturational arrest during thymocyte development with subsequent proliferation, survival, altered metabolism, and enhanced homing. These events are triggered by sequential accumulation of multiple genetic aberrations. Each case of T-ALL has on an average, more than ten genetic aberrations, which disrupt distinct intracellular pathways [23,37], including activation of oncogenic transcription factors, loss of tumor suppressor genes, increased kinase signaling, epigenetic lesions, and defective ribosomal proteins and RNA translation [23,37]. Table 1 enlists pathways and genes involved with the frequency and distribution among children and adults. CDKN2A/CDKN2B tumor suppressor genes and NOTCH1 transcription factor gene are the most common altered genes in T-ALL [23,37,38]. Mutations in NOTCH1 were identified in 50% of the 150 children with T-ALL treated on the ALL-Berlin-Frankfurt-Munster (BFM) 2000 study, and among them, 60% were in the heterodimerization domain, ~20% in the PEST domain, and ~20% in both domains [39]. NOTCH1 mutational status correlates with the common cortical immunophenotype [39]. Similarly, among 212 adult patients with T-ALL treated on the GRAALL-2003 and -2005 trials, NOTCH1 and FBXW7 mutations were identified in 67% [40]. Genome-wide sequencing techniques have identified more than 100 different genes that are mutated or rearranged in T-ALL [23,41]. Important among them are dysregulated expression of transcriptional factor genes. T-ALL subgroups that correlate with the intra-thymic stage of differentiation have been identified based on the unique and mutually exclusive transcriptional factor involved [23].

IL7R and JAK mutations are present in 20–30% of T-ALL cases leading to increased JAK/STAT signaling downstream of the IL7 receptor. These mutations are mostly observed in early cortical (TLX3/TLX1) and ETP-ALL (HOXA, LMO2/LYL1) subgroups [37,42–45]. Increased IL7R signaling is also noted in cases without these mutations, indicating the presence of other factors activating the IL7R pathway [37,46,47]. Episomal modifications are present in more than 50% of T-ALL cases and include DNMT3A, EED, EZH2, KDM6A, PHF6, and SUZ12 [37,48,49]. Non-germline somatic mutations in ribosomal protein genes RPL5, RPL10, and RPL22 are seen in 20% of T-ALL cases [37,50]. Oncogenic microRNAs can downregulate tumor suppressor genes such as IKZF1, PTEN, and FBXW7 [37]. Relapsed T-ALL exhibits NTSC2 enzyme gene mutations leading to increased nucleotidase activity and resistance to maintenance chemotherapy drugs 6-MP and 6-TG [37]. The cryptic fusion NUP214-ABL1 resulting in epigenetic amplification of ABL1 has been described in 5–10% of T-ALL cases [51,52] rendering them sensitive to inhibition by tyrosine kinase inhibitors Imatinib, Nilotinib, and Dasatinib [53]. NUP214-ABL1-mediated proliferation is SRC family kinase LCK-dependent and therefore dual ABL1/SRC kinase inhibitors Dasatinib and Bosutinib may be better suited for the treatment of this subtype of T-ALL [54]. Rare cases of BCR-ABL1 fusion have also been described [55,56].
Table 1. Altered pathways, genes, and their frequencies in T-ALL [23,37,41].

| Pathway                        | Genes                        | Frequency (Children) | Frequency (Adults) |
|--------------------------------|------------------------------|----------------------|--------------------|
| NOTCH signaling                | NOTCH1 FBXW7                 | 75%                  | >50%               |
| Cell cycle, tumor suppression  | CDKN2A/CDKN2B, CDKN1B, CCND3, RBL | >70%                 | >45–55%            |
| Transcription                  | TAL1, TLX1, TLX3, LMO2, LYL1, HOXA, NKX2-1, BCL11B and others | >90%                 | >90%               |
| Intracellular signaling        | JAK1, JAK3, STASB, IL7R, KRAS, NRAS, PTEN, PIK3CA, FLT3, ABL1 | >60%                 | >60%               |
| Epigenetic modification        | DNMT3A, EZH2, TET2, IDH1, IDH2, SUZ12, EP300, MLL2, WHSC1 | >35%                 | >60%               |
| Ribosomal function             | RPL5, RPL10, RPL22           | >10%                 | >10%               |
| RNA translation                | mTOR, CNOT3                  | ~9%                  | ~9%                |

PICALM-MLL10 is the most common fusion protein in T-ALL and is seen in 6–7% of pediatric and adult T-ALL [57]. This fusion results in upregulation of HOXA genes [58] as do MLL-AF6, SET-NUP214, and TCRB-HOXA [59,60]. It is interesting to note that PICALM and HOXA aberrations are also seen in AML [61,62].

2.4. Prognostic Significance of Genomic Aberrations in T-ALL

NOTCH1 mutations correlate with good prednisone response, favorable MRD kinetics, and long-term outcomes in pediatric patients treated on ALL-BFM protocols [39]. In the FRALLE2000T study, among 220 children with T-ALL, the favorable prognostic significance of NOTCH1/FBXW7 mutations was restricted to patients without RAS/PTEN mutations [63]. In the UKALL2003 trial, among 162 pediatric T-ALL patients, outcomes correlated with the number of mutations, with five-year OS 82, 88, and 100% for NOTCH1/FBXW7 wildtype, NOTCH1 mutated/FBXW7 wildtype, and NOTCH1/FBXW7 double mutated, respectively [64]. However, in the UKALLXII/E2993 trial, among 88 adult T-ALL patients, there was no significant difference in disease response based on NOTCH1 and FBXW7 mutations [65]. In the GMALL 05/93 and 06/99 trials, among 126 adult T-ALL patients, NOTCH1 and FBXW7 mutations were associated with favorable outcomes but only with low expression of ERG and BAALC [66]. High expression of ERG and BAALC has been associated with an immature leukemic phenotype and the above result could indicate a more differentiated leukemia that is susceptible to combination chemotherapy. In the GRAALL-2003 and -2005 trials with 212 adult T-ALL patients, RAS/PTEN mutations conferred poor prognosis and NOTCH1/FBXW7 mutations conferred favorable prognosis but only in the absence of RAS/PTEN abnormalities [40]. Other studies have also shown high-risk disease and poor prognosis with PTEN mutations [67–69]. Mutational loss of PTEN has been linked to resistance to pharmacological inhibition of NOTCH1 with γ-secretase inhibitors [70].

3. Immunophenotypic Classification

The immunophenotypic characteristics of T-ALL lymphoblasts reflects the intra-thymic stage at which differentiation arrest takes place. The WHO 2008/2016 criteria for T-lineage assignment uses strong cytoplasmic (Cy) or surface (S) CD3 [10]. The EGIL classification similarly defines T-ALL by Cy or S expression of CD3 and subgroups T-ALL as follows [71]:
1. Pro-T: CD7+, CD2−, CD5−
2. Pre-T: CD2+, CD5+/−, CD8+/−
3. Cortical-T: CD1a+
4. Mature-T: sCD3+, CD1a−

Another classification was based on immunophenotype of patients treated in three consecutive GMALL studies, 05/93, 06/99, and 07/2003. T-ALL was defined by the presence of cyCD3 and CD7 and was subclassified as follows [8]. Figure 1 depicts the distribution of cases in these three studies.

1. Early T-ALL—sCD3−, CD1a−
2. Thymic T-ALL—sCD3−/+ , CD1a+
3. Mature T-ALL—sCD3+, CD1a−

Although the latter classification is more commonly used for immunophenotypic subtyping, the prognostic impact of either system is limited, with the exception of Early T-ALL, the prognostic significance of which is described below.

![Maturational Stages of T-ALL with genetic alterations](image)

**Figure 1.** Maturational stages of T-ALL color-coded with associated genetic alterations [23,37]. Transcription factors affected are indicated in ovals within the subtype and gene alterations are depicted outside the subtypes. Genes in green ovals are altered across different subtypes.

**Early T Precursor Cell ALL (ETP-ALL)**

ETP-ALL is a subtype of T-ALL with distinct genetic and immunophenotypic characteristics. It comprises 12-20% of T-ALL cases in children and adults [72,73]. The immunophenotype of ETP-ALL is defined as CD1a−, CD8−, CD5−/weak along with the expression of one or more myeloid or stem cell markers such as CD117, CD34, HLA-DR, CD13, CD33, CD11b, and CD65 [72]. The leukemic cells derive from immature thymocytes that retain stem cell and myeloid lineage characteristics. Defects in transcriptional factors LMO2, LYL1, and HOXA and mutations in IKZF1 and MED12 and rearrangement of NUP98 as well as myeloid malignancy mutations such as FLT3, WTI, EZH2, RAS, RUNX1, and NPM1 are also seen [23,46,74–76]. In the GRAALL-2003 and -2005 studies, HOXA overexpression was associated with poor prognosis in adults with ETP-ALL. The five-year OS was 31% and 74% in HOXA positive and negative cases, respectively [77]. In this study, among the non-ETP cases, there was no difference in outcomes, with five-year OS being
66% and 57% in HOXA positive and negative patients, respectively. Compared to non-ETP, ETP leukemic cells tend to lack molecular markers for polymerase chain reaction (PCR) detection of minimal/measurable residual disease (MRD), be steroid resistant, and patients are more likely to present with CNS and extramedullary disease and have poor response to induction [78]. However, the use of response-based risk stratification and therapy intensification was shown to abrogate the poor prognosis of adult ETP-ALL in the GRAALL-2003 and -2005 studies [79]. On the other hand, adults with ETP-ALL treated on the HyperCVAD protocol had poor outcomes [73]. In children and young adults with ETP-ALL, although earlier studies reported poor outcomes compared to non-ETP-ALL [72], with the current use of intensified pediatric regimens, outcomes are comparable in both groups [80].

4. Risk Stratification and Measurable Residual Disease (MRD)

4.1. Children’s Oncology Group (COG) Risk Groups

The COG risk stratifies pediatric T-ALL as depicted below [81]. M1, 2, and 3 marrow indicate <5%, 5–25%, and >25% blasts, respectively. CNS1 indicates <5 WBC/µL with no blasts in CSF. MRD was determined by flow cytometry at a central lab.

**Standard risk**—Day 29 M1 marrow and MRD < 0.01%, CNS1, no testicular disease and no steroid pretreatment

**Intermediate risk**—Day 29 M1 or M2 marrow and MRD >/= 0.01%, end of consolidation MRD < 0.1%, any CNS/testicular disease status, any steroid pretreatment status

**Very high risk**—Day 29 M3 marrow or end of consolidation MRD >/= 0.1%

4.2. UKALL Risk Stratification

The UKALL 2003 study risk stratified ALL patients ages 1–24 years using three parameters [82]:

1. National Cancer Institute (NCI) risk criteria—NCI standard risk—age < 10 years and WBC < 50,000/µL, NCI high risk—age ≥ 10 years and WBC ≥ 50,000/µL
2. Cytogenetics—MLL gene rearrangement, hypodiploidy and iAMP21 were considered high risk
3. Response to induction therapy in age < 16 years—day 8 or 15 bone marrow with < or >25% blasts

Based on above parameters, three clinical risk groups were identified:

1. Clinical standard risk—NCI standard risk with <25% blasts at day 15 after induction and without high-risk cytogenetics
2. Clinical intermediate risk—NCI high risk with <25% blasts at day 8, all patients ≥ 16 years irrespective of day 8 or 15 marrow response
3. Clinical high risk—high-risk cytogenetics as noted above, NCI high risk with >25% blasts at day 8, NCI standard risk with >25% blasts at day 15

Clinical standard and intermediate risk patients were further stratified based on MRD response (determined at 10−4 range as assessed by PCR of Ig or TCR gene rearrangement), at the end of induction and consolidation.

1. MRD low risk—MRD undetectable before start of interim maintenance, with undetectable or detectable at <0.01% MRD at the end of induction
2. MRD intermediate risk—MRD could not be measured or MRD positive at <0.01% before start of interim maintenance
3. MRD high risk—MRD at least 0.01% at the end of induction

4.3. MRD

Although clinical risk factors such as age, WBC at presentation, presence of CNS disease [11], and genetic abnormalities such as RAS and PTEN mutations [40] have prognostic significance, MRD remains the single most important prognostic indicator in pediatric and young adult T-ALL as demonstrated in multicenter cooperative group trials [83,84]. MRD can be measured by multi-color flow cytometry or polymerase chain reaction (PCR) of clonal T-cell receptor (TCR) gene rearrangements with a sensitivity of 10−4 for both method-
ologies [85]. Unlike B-ALL where a high percentage of pediatric and young adult patients achieve early MRD negativity, more than 80% of T-ALL patients remain MRD positive at the end of induction as demonstrated in the AIEOP-BFM-ALL 2000 study [86]. In this study, the seven-year EFS was 91, 80, and 50% with negative MRD after induction, negative MRD after consolidation, and persistent MRD after consolidation, respectively [86]. In the UKALL 2003 study, there was no significance reduction in the five-year EFS in low MRD-risk patients who received one versus two delayed intensification regimens, suggesting that treatment reduction is feasible in this risk subgroup [82]. While end of induction MRD may help identify patients eligible for reduced intensity therapy, end of consolidation (EOC) MRD can identify patients at high risk of relapse who would benefit from allogeneic stem cell transplant (HSCT) [86–89].

5. Frontline Treatment

While multiagent chemotherapy regimens remain the cornerstone of first line therapy in children and adults, the regimens used, and the outcomes observed in T-ALL differ between the two age groups and will therefore be discussed separately. Until the advent of Neltarabine, B-ALL and T-ALL patients were treated similarly in clinical trials. For pediatric ALL as a whole, five-year overall survival (OS) has improved from <20% in the 1960s to >90% since 2000, and for T-ALL the 5-year OS reached ~80% in 2000 [11].

5.1. Children, Adolescents, and Young Adults (AYAs)

The past several decades has seen a steady improvement in the survival of children and AYAs with T-ALL primarily due to incremental and strategic changes in multiagent chemotherapy regimens in children and the adoption of pediatric-inspired protocols in young adults [11,90]. We will discuss treatment in this age group in the context of the following advances which are depicted in Figure 2. Table 2 summarizes the recent studies.

1. **Intensification of induction and consolidation**—This includes using a four-drug induction regimen containing a steroid (dexamethasone or prednisone), anthracycline, vincristine, and asparaginase and an augmented Berlin-Frankfurt-Munster (BFM)-based consolidation regimen using cyclophosphamide [9,87,91–93].

2. **Use of dexamethasone (DEX) instead of prednisone (PRED) during induction**—Both DEX and PRED as the steroid of choice during induction in pediatric ALL have been studied in several trials. DEX being more potent and capable of CNS penetration, has been shown to decrease overall and CNS relapse. In the AIEOP-BFM ALL 2000 study, a significant survival benefit was observed with DEX for T-ALL patients [94]. Similarly, in the UK MRC ALL97 and ALL97/99, DEX demonstrated a lower risk of isolated CNS relapse and improved EFS compared to prednisolone [95,96]. Subsequently, the UKALL 2003 used only DEX and the T-ALL patients had superior outcomes with three-year EFS 86% and OS 90% [97]. The use of DEX was shown to have a higher risk of infections and other toxicity [94] and warrants careful monitoring of these patients. Although the COG AALL0434 reported excellent outcomes using PRED in T-ALL, in this study, all intermediate risk (IR) and high risk (HR) patients received cranial radiation, which confounds the lack of CNS relapse with PRED.

3. **Omitting routine prophylactic cranial radiation (CRT)**—In order to decrease toxicity and yet maintain efficacy, several cooperative group studies in the US and Europe omitted prophylactic CRT and intensified systemic and intrathecal therapy in pediatric ALL and have shown this strategy to be effective with low rates of CNS relapse between ~3–8% in T-ALL patients and comparable to those who received CRT [98–103]. The intensification strategies used varied between the different trials and included combinations of triple intrathecal therapy, high dose methotrexate, higher asparaginase doses, and use of DEX, but nevertheless, demonstrated that prophylactic CRT can be safely eliminated in most pediatric patients with T-ALL.

4. In the context of using **DEX and minimizing CRT**, the COG AALL1231 combined both these strategies [104]. This was a phase three trial that randomized T-ALL/LL
patients ages 1–30 years, to a modified augmented BFM backbone with or without Bortezomib during induction and delayed intensification (DI). Only the very high risk (VHR) patients as defined by day 29 M3 marrow, EOC MRD > 0.1% or overt CNS leukemia (CNS3), received cranial radiation. Following the MRC strategy, DEX was used instead of PRED and an extra dose of PEG-ASP was added to induction and DI. While standard risk (SR) and intermediate risk (IR) patients had improved three-year EFS with Bortezomib (>90% vs. 85% for both groups, \( p < 0.05 \)), VHR patients did worse with Bortezomib with three-year EFS of 37% vs. 6% \( (p = 0.03) \) [104]. However, the study closed early (when Nelarabine was shown to improve DFS in AALL0434), and it was not sufficiently powered to determine the effect of adding Bortezomib to chemotherapy backbone to the entire T-ALL cohort irrespective of risk status.

5. **Nelarabine** is a purine nucleoside analog, a prodrug of Ara-G, and cytotoxic to T lymphoblasts. It has been shown to have single agent activity in relapsed T-ALL with high CNS penetration and therefore has potential to decrease CNS relapse, but this comes with the risk of CNS toxicity [105]. Therefore, Nelarabine should not be used with IT chemotherapy and cannot be used in patients with active CNS disease, as these patients will be receiving IT chemotherapy.

6. **Addition of Nelarabine and comparison of high dose (HD) versus Capizzi (escalating doses) methotrexate (C-MTX)** were tested in a randomized fashion in the COG AALL0434 study. Prior to COG AALL0434, the COG AALL0232 had demonstrated that in B-ALL, HD-MTX and DEX improved outcomes compared to C-MTX and PRED [106]. Since disease sensitivity to MTX can vary between B and T-ALL, the COG tested these two strategies in T-ALL in the AALL0434 trial [80]. In addition, since Nelarabine was shown to have superior activity in the relapsed/refractory setting, use of Nelarabine in the upfront setting was tested in a randomized fashion. As a result, AALL0434 had a 2 × 2 factorial design comparing HD-MTX to C-MTX with and without Nelarabine added to the BFM backbone. From 2007 to 2014, this study enrolled 1562 patients with T-ALL, ages 1–31 years, and used an augmented BFM regimen with PRED as steroid and with a 2 × 2 randomization to receive either an escalating dose of MTX (C-MTX) or HD-MTX. All patients with IR and HR disease also received prophylactic CRT and were randomized to receive or not receive Nelarabine. In contrast to the B-ALL results from the COG AALL 0232, where HD-MTX had improved outcomes, C-MTX produced better outcomes in T-ALL with five-year DFS of 91% vs. 83%, \( p = 0.04 \) and OS 93% vs. 89%, \( p = 0.04 \) [107]. While the addition of Nelarabine improved five-year DFS (88% vs. 82%, \( p = 0.03 \)), the improvement in five-year OS (90% vs. 88%, \( p = 0.168 \)) did not reach statistical significance [80]. Overall, the five-year DFS was highest with C-MTX with Nelarabine and lowest with HD-MTX without Nelarabine (91% vs. 78%, \( p = 0.01 \)). Another significant finding from this trial was the decrease in CNS relapse rate with Nelarabine (1.3% vs. 6.9%, \( p = 0.0001 \)). In the context of Nelarabine, the UKALL 14, is an ongoing randomized phase III trial, where adult T-ALL patients are randomized to receive standard chemotherapy with or without Nelarabine (NCT01085617). In addition, the GRAALL-2014/T is a multicenter study of risk-adapted treatment for T-ALL in young adults ages 18–59 years, evaluating the efficacy of a Nelarabine-based consolidation and maintenance in high-risk patients (NCT02619630).

7. **Role of allogeneic hematopoietic stem cell transplant (HSCT) in children with T-ALL**—with the high rates of long-term progression free and overall survival achieved with contemporary, intensive pediatric regimens described above, the indications for HSCT in children with T-ALL is decreasing. Persistence of MRD at \( 10^{-3} \) or \( 10^{-4} \) post consolidation remains the primary indication for HSCT. While HSCT remains an option in very high-risk (VHR) disease (Day 29 M3 marrow, CNS3) [103], many experts recommend using EOC MRD as the primary indication for HSCT [108]. ETP-ALL alone is not considered an indication for HSCT in children as long as they can achieve MRD negativity post consolidation [108].
8. **Incorporating precision medicine strategies**—ALLTogether1 is a prospective observational study designed by seven cooperative groups in Europe (NOPHO, UKALL, DCOG, COALL, BSPHO, SHOP, and SFCE) using a common treatment protocol based on a novel personalized algorithm using clinical characteristics, genetic changes, and response to treatment for patients ages 1–45 years with newly diagnosed B and T-ALL (NCT03911128). Total Therapy XVII is the equivalent study in the US enrolling B and T-ALL patients with the objective of using novel precision medicine strategies based on genomic features of the leukemia and tailoring treatment for individual risk groups. The T-ALL cohort would receive, in addition to combination chemotherapy, a targeted agent such as Dasatinib, Bortezomib, or Ruxolitinib depending on the respective aberration detected (NCT03117751).

![Diagram](image)

**Figure 2.** Strategic Advances in the Management of Pediatric T-ALL.

**Table 2.** Recent studies in pediatric and AYA T-ALL.

| No. | Name of Trial | Years of Enrollment | Age Range (y) | Steroid Used | Cranial Radiation | Novel Agent Used | DFS and OS in T-ALL Patients | Ref |
|-----|---------------|---------------------|---------------|--------------|------------------|------------------|-----------------------------|-----|
| 1.  | CALGB 10403   | 2007–2012           | 71            | Pred *       | Yes—in all T-ALL | None             | 3 y DFS 66% 3 y OS 73%      | [7] |
| 2.  | COG AALL0434  | 2007–2014           | 1562          | Pred         | Yes—in IR and HR groups ** | Nelarabine      | 5 y EFS 83% 5 y OS 89%      | [80] |
| 3.  | COG AALL1231  | 2014–2017           | 847           | Dex          | Only in VHR † group | Bortezomib      | 3 y EFS 83% 3 y OS 86%      | [104] |
| 4.  | NOPHO ALL2008 | 2008–2014           | 231           | Dex          | No               | None             | 5 y EFS 74% 5 y OS 75%      | [109] |
| 5.  | Total therapy XVI | 2007–2017         | 104           | Pred         | No               | None             | 5 y EFS 81% 5 y OS 87%      | [103] |

* Pred—prednisone. Dex—dexamethasone ** IR—intermediate risk, HR—high risk † VHR—very high risk: Day 29 M3 marrow, EOC MRD > 0.1%, CNS3.
5.2. Use of Pediatric-Inspired Regimens in Young Adults

Inspired by the superior outcomes achieved in childhood ALL with intensive multiantgent chemotherapy regimens, adult oncology groups adopted and prospectively studied these regimens in young adult ALL and demonstrated both feasibility and efficacy [110–113]. The Cancer and Leukemia Group B (CALGB) 8811 used a five-drug induction regimen similar to CCG-192P and a BFM-based consolidation [111] with higher doses of cyclophosphamide and earlier and more extensive use of L-asparaginase. Patients with T-ALL comprised 22% of the cohort and achieved a comparable three-year DFS (57%) to B-ALL patients. Other groups including GRAALL and PETHEMA have shown similar outcomes using pediatric regimens in young adult patients [114–117]. Encouraged by these positive results demonstrating feasibility and efficacy, the CALGB 10403 sought to further demonstrate that pediatric protocols can be safely administered to young adults by oncologists treating adult patients [7]. From 2007 to 2012, CALGB 10403 enrolled 318 adolescent and young adults (AYAs) ages 17–39 years, with B- and T-ALL, with the latter constituting 24% of the cohort and used a regimen that was identical to the C-MTX arm of COG AALL0232 with four intensive courses that included induction, consolidation, interim maintenance, delayed intensification, and a prolonged maintenance. PRED was used during induction and DEX during delayed intensification and maintenance. Patients with T-ALL received 24 Gy prophylactic cranial irradiation. There were no significant differences in the outcomes between B and T-ALL, with three-year DFS and OS being 66 and 73%, respectively, for the whole cohort [7]. Most experts recommend a pediatric-inspired regimen as the preferred choice in AYAs with Ph-negative B-ALL and T-ALL [118].

5.3. Older Adults with T-ALL

Clinical data on the outcomes of older adults with T-ALL are sparse. The largest study of older adults with ALL was conducted by GMALL, in which 268 patients 55–85 years with ALL were enrolled and treated with pre-phase, induction, consolidation, reinduction, and prolonged maintenance, along with triple chemotherapy CNS prophylaxis. T-ALL comprised 15% of the cohort. OS at five years was 23% for the whole cohort and immunophenotype did not correlate with OS [119].

HyperCVAD is commonly used in adults with ALL. In a study from MDACC, 40 patients with T-ALL, ages 18–78 years were treated with hyperCVAD + Nelarabine, and three-year OS was 62%. Outcomes were not analyzed by age. When sub-grouped by immunophenotype, ETP-ALL (n = 15), appeared to have worse outcomes with three-year OS of 50%, although this difference was not statistically significant (p = 0.59), likely due to low sample number [120]. Two studies published outside MDACC have reported poor outcomes in adult T-ALL with hyperCVAD [121,122].

In the UKALLXII/ECOG2993, 356 out of 1643 ALL patients (22%), ages 15–59 years, were designated as T-ALL based on intracytoplasmic CD3. T-ALL comprised 38 and 10% of ALL in patients ages 20–29 years and >50 years, respectively, demonstrating the rarity of this disease in the older patients [113]. The five-year OS was 48% for T-ALL of all ages and not statistically different from B-ALL. However, in patients older than 50 years, five-year OS was only 27% compared to >50% for <30 years.

In conclusion, older patients with T-ALL fare worse likely due to a combination of adverse risk disease biology and higher complications from treatment related to underlying comorbidities. More studies in this subgroup are required to tailor treatment to fit disease and patient profile.

5.4. Role of Allogeneic Stem Cell Transplant in Adults with T-ALL

While persistent MRD is the primary indication for HSCT in children with T-ALL, adults with high-risk T-ALL fare poor and therefore have a lower threshold to transplant. Indications for HSCT in adults include high-risk disease at presentation (WBC > 100 k/µL, CNS or other extramedullary disease, ETP-ALL, complex karyotype), poor response to induction, persistence of MRD, and of course, relapsed disease with CR2 or beyond [123,124].
The UKALLXII/ECOG2993 trial studied 356 T-ALL patients, of which, 110 had a sibling donor. HSCT was associated with lower relapse (25% vs. 51%, \( p < 0.0001 \)), higher non-relapse mortality (22% vs. 12%, \( p = 0.02 \)), and improved five-year OS (61% vs. 46%, \( p = 0.02 \)). Among 57 patients with ETP-ALL treated in the GMALL studies (05/93-07/03), ~60% received HSCT in first CR and derived benefit with OS being comparable to non-ETP patients [75]. Intensity of conditioning regimen in older patients has been studied extensively. The increased toxicity and NRM of myeloablative conditioning needs to be considered against the potentially increased relapse rate with reduced intensity conditioning [125].

6. Relapsed/Refractory (R/R) Disease and Targeted Therapies

Both children and adults with relapsed disease have poor outcomes. OS rates in children are ~25% [126,127] and similar in adults as well [128].

In children with relapsed disease, re-induction is recommended followed by HSCT if the patient achieves remission [129]. The UKALL R3 multidrug reinduction regimen produced better outcomes with Mitoxandron compared to idarubicin with three-year PFS and OS of 65 and 69%, respectively [130]. NECTAR (NCT00981799) was a phase 1 study of Nelarabine with etoposide and cyclophosphamide in patients 1–21 years of age with T-ALL and T-LL in first relapse. Among nine patients with T-ALL, 44% had a response rate.

The BCL2 inhibitor Venetoclax has been studied in combination with the BCL-X and BCL-2 inhibitor Navitoclax in a phase 1 study in children and adults with relapsed/refractory ALL, of which, 19 patients had T-ALL [131]. The overall CR was 60% and 28% proceeded to transplant or CAR-T cell therapy [131]. There are case reports of Venetoclax with Decitabine [132,133] and a case report of Venetoclax with chemotherapy [134] demonstrating efficacy in patients with relapsed ETP-ALL allowing for consolidation with HSCT. The authors themselves have successfully treated a young adult patient with ETP-ALL who relapsed after myeloablative double umbilical cord transplant, achieved an MRD negative remission with Venetoclax and Decitabine, and has proceeded to a second HSCT with reduced intensity conditioning and a haploidentical donor. The combination of Venetoclax and Bortezomib was shown to be effective in a case series of three patients, with two of them achieving cytogenetic remission and proceeding to HSCT at the eight-month follow-up [135].

The COG AALL07P1 was a phase 2 trial in children with relapsed ALL and LL, of which, 22 were T-ALL. Reinduction regimen included chemotherapy with Bortezomib. CR2 rate was 68% in T-ALL [136]. Following this encouraging response, the COG AALL1231 added BOR to induction in a randomized fashion and the results are as described in Section 5.1.

Daratumumab and Isatuximab, monoclonal antibodies directed against CD38, have safety profile in humans based on clinical studies in multiple myeloma [137,138]. Preclinical models and case reports have demonstrated the efficacy of DARA in T-ALL. Based on these data, a phase 2 study is underway to evaluate the safety and efficacy of Daratumumab added to standard chemotherapy in patients ages 1–30 years with relapsed/refractory B and T-ALL and LBL (NCT03384654). Primary endpoint is complete remission after one cycle for T-ALL and two cycles for B-ALL. Isatuximab is being studied with chemotherapy in phase 1/2 study (NCT03817320).

NUP214-ABL1 fusion resulting in ABL1 amplification has been described in 5–10% of T-ALL cases [51,52], rendering them sensitive to tyrosine kinase inhibitors Imatinib, Nilotinib, and Dasatinib [53]. The first case report of a young adult with NUP214-ABL1 positive T-ALL achieving complete remission with single agent Dasatinib was reported in 2009 [139]. Another case report of a pediatric T-ALL with ABL1 amplification achieving complete remission after the addition of Dasatinib to chemotherapy was reported in 2012 [140]. Although rare, a single case was reported of a young adult with ETP-ALL with NUP214-ABL1 fusion successfully treated with Dasatinib added to chemotherapy [141]. There are also case reports of T-ALL with BCR-ABL1 fusion [55,56].
Given the preclinical efficacy of targeting cell cycle regulators CDK4 and 6 [142], the COG launched AINV18P1 (NCT03792256). Patients aged 1–30 years with relapsed B or T-ALL or LL receive the CDK4/6 inhibitor Palbociclib initially as a single agent and subsequently with chemotherapy. Preliminary results demonstrate safety and the expansion phase of this trial is ongoing [143]. Last but not the least, chimeric antigen receptor (CAR) T cell therapy has now entered the realm of T-ALL. A phase 1 pilot study of CD7 targeting CAR-T has demonstrated lack of fratricide and CR in five out of eight enrolled patients with minimal toxicity [144].

Preclinical data demonstrate activation of the JAK/STAT signaling pathway in ETP-ALL and the efficacy of the JAK inhibitor Ruxolitinib in xenograft models of ETP-ALL [45]. The PI3K/AKT/mTOR pathway is shown to be activated in T-ALL due to PTEN inactivation, and inhibition of this pathway has demonstrated efficacy in preclinical models of T-ALL [145]. Combined targeting of CDK and mTOR is being studied in a phase 1 trial of Ribociclib with Everolimus and DEX in patients ages 1–30 years with relapsed/refractory B and T-ALL (NCT03740334). While the development of non-specific γ-secretase inhibitors was hampered by toxicity, the presenilin-1 (PSEN1) subunit γ-secretase inhibitor has demonstrated activity in preclinical models of NOTCH-mutated T-ALL with minimal toxicity and may have therapeutic potential [25].

7. Conclusions

Tremendous progress has been made in uncovering the genetic underpinnings of T-ALL. Yet, several more defects remain to be discovered. Comparable progress in outcomes has been achieved with combination chemotherapy regimens especially in children and young adults, and yet, toxicities of these regimens remain significant. MRD has emerged as the most prominent risk factor to act upon. As we enter the era of targeted therapies, one can hope to improve outcomes further especially in older adults and decrease toxicity and improve long-term quality of life for children and young adults. Attempts to increase enrollment in clinical trials and eliminate racial and geographic disparities in access to high volume centers are essential for improving outcomes and should be emphasized.

Author Contributions: P.S. prepared, edited and approved the manuscript. W.J. and V.A. edited, and approved the manuscript. W.J. and V.A. contributed equally. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. SEER Database. 2021. Available online: https://seer.cancer.gov/statfacts/html/alyl.html (accessed on 29 October 2021).
2. European Environment and Health Information System/WHO. 2009. Available online: https://www.euro.who.int/__data/assets/pdf_file/0005/97016/4.1.-Incidence-of-childhood-leukaemia-EDITED_layouted.pdf (accessed on 29 October 2021).
3. Dong, Y.; Shi, O.; Zeng, Q.; Lu, X.; Wang, W.; Li, Y.; Wang, Q. Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. Exp. Hematol. Oncol. 2020, 9, 14. [CrossRef]
4. Colunga-Pedraza, P.R.; Gomez-Cruz, G.B.; Colunga-Pedraza, J.E.; Ruiz-Argüelles, G.J. Geographic Hematology: Some Observations in Mexico. Acta Haematol. 2018, 140, 114–120. [CrossRef] [PubMed]
5. Dores, G.M.; Devesa, S.S.; Curtis, R.E.; Linet, M.S.; Morton, L.M. Acute leukemia incidence and patient survival among children and adults in the United States, 2001–2007. Blood 2012, 119, 34–43. [CrossRef]
6. Goggins, W.B.; Lo, F.F.K. Racial and ethnic disparities in survival of US children with acute lymphoblastic leukemia: Evidence from the SEER database 1988–2008. Cancer Causes Control. 2012, 23, 737–743. [CrossRef]
7. Stock, W.; Lugger, S.M.; Advani, A.S.; Yin, J.; Harvey, R.C.; Mullighan, C.G.; Willman, C.L.; Fulton, N.; Laumann, K.M.; Malnassy, G.; et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: Results of CALGB 10403. Blood 2019, 133, 1548–1559. [CrossRef] [PubMed]
8. Hoelzer, D.; Thiel, E.; Arnold, R.; Beck, J.; Beelen, D.W.; Bornhäuser, M.; Bunjes, D.; Ditz, D.; Dührsen, U.; Finke, J.; et al. Successful Subtype Oriented Treatment Strategies in Adult T-ALL: Results of 744 Patients Treated in Three Consecutive GMALL Studies. *Blood* 2009, 114, 324. [CrossRef]

9. Pui, C.-H.; Sandlund, J.T.; Fei, D.; Campagna, D.; Rivera, G.K.; Ribeiro, R.C.; Rubnitz, J.E.; Razzouk, B.I.; Howard, S.C.; Hudson, M.M.; et al. Improved outcome for children with acute lymphoblastic leukemia: Results of Total Therapy Study XIII at St Jude Children’s Research Hospital. *Blood* 2004, 104, 2690–2696. [CrossRef]

10. Arber, D.A.; Orazi, A.; Hasserjian, R.; Thiele, J.; Borowitz, M.J.; Le Beau, M.M.; Bloomfield, C.D.; Cazzola, M.; Vardiman, J.W. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood* 2016, 127, 2391–2405. [CrossRef]

11. Hunger, S.P.; Mullighan, C.G. Acute Lymphoblastic Leukemia in Children. *N. Engl. J. Med.* 2015, 373, 1541–1552. [CrossRef]

12. Jain, P.; Kantarjian, H.; Ravandi, F.; Thomas, D.; O’Brien, S.; Kadia, T.; Burger, J.; Borthakur, G.; Daver, N.; Jabbour, E.; et al. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. *Leukemia* 2014, 28, 973–975. [CrossRef]

13. Shah, D.K.; Zúñiga-Pflücker, J.C. An Overview of the Intrathymic Intricacies of T Cell Development. *J. Immunol.* 2014, 192, 4017–4023. [CrossRef]

14. Sanchez-Martin, M.; Ferrando, A. The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia. *Blood* 2017, 129, 1124–1133. [CrossRef] [PubMed]

15. Rodriguez, H.R.; Kretzschmar, K.; Swat, W.; Takeda, S. Intrathymically expressed c-kit ligand (stem cell factor) is a major factor driving expansion of very immature thymocytes in vivo. *Immunity* 1995, 3, 313–319. [CrossRef]

16. D’Souza, B.; Miyamoto, A.; Weinmaster, G. The many facets of Notch ligands. *Oncogene* 2008, 27, 5148–5167. [CrossRef]

17. Koch, U.; Fiorini, E.; Benedito, R.; Besseyrias, V.; Schuster-Gossler, K.; Pires, M.; Manley, N.R.; Duarte, A.; Macdonald, H.R.; Radtke, F. Delta-like 4 is the essential, nonredundant ligand for Notch1 during thymic T cell lineage commitment. *J. Exp. Med.* 2008, 205, 2515–2523. [CrossRef] [PubMed]

18. Huang, E.Y.; Gallegos, A.M.; Richards, S.M.; Lehar, S.M.; Bevan, M.J. Surface expression of Notch1 on thymocytes: Correlation with the double-negative to double-positive transition. *J. Immunol.* 2003, 171, 2296–2304. [CrossRef] [PubMed]

19. Gordon, W.R.; Roy, M.; Vardar-Ulu, D.; Ribeiro, G.K.; Mansour, M.R.; Aster, J.C.; Blacklow, S.C. Structure of the Notch1-negative regulatory region: Implications for normal activation and pathogenic signaling in T-ALL. *Blood* 2009, 113, 4381–4390. [CrossRef]

20. Wu, L.; Auster, J.C.; Blacklow, S.C.; Lake, R.; Artavanis-Tsakonas, S.; Griffin, J.D. MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors. *Nat. Genet.* 2000, 26, 484–489. [CrossRef]

21. Grim, J.E.; Sala, O.; Chung, N.G.; Radich, J.; Varnum-Finney, B.J.; Bernstein, I.D.; Clurman, B. Notch Regulation by the Fbw7/hcd4/Sel-10 Ubiquitin Ligase. *Blood* 2006, 108, 1420. [CrossRef]

22. Weng, A.P.; Ferrando, A.A.; Lee, W.; Morris, J.P.T.; Silverman, L.B.; Sanchez-Irizarry, C.; Blacklow, S.C.; Look, A.T.; Aster, J.C. Activating mutations of NOTCH1 in human t cell acute lymphoblastic leukemia. *Science* 2004, 306, 269–271. [CrossRef] [PubMed]

23. Liu, Y.; Easton, J.; Shao, Y.; Maciaszek, J.; Wang, Z.; Wilkinson, M.R.; McCastlain, K.; Edmonson, M.; Pounds, S.B.; Shi, L.; et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. *Nat. Genet.* 2017, 49, 1211–1218. [CrossRef] [PubMed]

24. Agnusdei, V.; Minuzzo, S.; Frasson, C.; Grassi, A.; Axelrod, F.; Satyal, S.; Gurney, A.; Hoey, T.; Seganfredo, E.; Basso, G.; et al. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts. *Leukemia* 2014, 28, 278–288. [CrossRef] [PubMed]

25. Habels, R.A.; de Bock, C.E.; Serneels, L.; Lodewijckx, I.; Verbeke, D.; Nittner, D.; Narlawar, R.; Demeyer, S.; Dooley, J.; Liston, A.; et al. Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition. *Sci. Transl. Med.* 2019, 11, 5. [CrossRef] [PubMed]

26. Chen, H.; Liu, H.; Qing, G. Targeting oncogenic Myc as a strategy for cancer treatment. *Signal Transduct. Target. Ther.* 2018, 3, 5. [CrossRef] [PubMed]

27. Wilson, A.; Murphy, M.J.; Oskarsson, T.; Kaloulis, K.; Bettes, M.D.; Oser, G.M.; Pasche, A.C.; Knabenhans, C.; Macdonald, H.R.; Trumpf, A. c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. *Genes Dev.* 2004, 18, 2747–2763. [CrossRef] [PubMed]

28. Vallespin, M.; Fernández, D.; Rodríguez, L.; Alvaro-Blanco, J.; Baena, E.; Ortiz, M.; Dukovska, D.; Martinez, D.; Rojas, A.; Campanero, M.R.; et al. B Lymphocyte commitment program is driven by the proto-oncogene c-Myc. *J. Immunol.* 2011, 186, 6726–6736. [CrossRef]

29. Wang, R.; Dillon, C.P.; Shi, L.Z.; Milasta, S.; Carter, R.; Finkelstein, D.; McCormick, L.L.; Fitzgerald, P.; Chi, H.; Munger, J.; et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. *Immunity* 2011, 35, 871–882. [CrossRef]

30. Nguyen, L.; Papenhausen, P.; Shao, H. The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects. *Genes* 2017, 8, 116. [CrossRef] [PubMed]

31. Manso, R.; Bellas, C.; Martín-Acosta, P.; Mollejo, M.; Menárguez, J.; Rojo, F.; Llamas, P.; Piris, M.A.; Rodríguez-Pinilla, S.M. C-MYC is related to GATA3 expression and associated with poor prognosis in nodal peripheral T-cell lymphomas. *Haematologica* 2016, 101, e336–e338. [CrossRef]
32. Douglas, N.C.; Jacobs, H.; Bothwell, A.L.M.; Hayday, A.C. Defining the specific physiological requirements for c-Myc in T cell development. *Nat. Immunol.* 2001, 2, 307–315. [CrossRef]

33. Palomero, T.; Lim, W.K.; Odem, D.T.; Sulis, M.L.; Rea, P.J.; Margolin, A.; Barnes, K.C.; O’Neill, J.; Neuberg, D.; Weng, A.P.; et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. *Proc. Natl. Acad. Sci. USA* 2006, 103, 18261–18266. [CrossRef]

34. Herranz, D.; Ambesi-Impiombato, F.; Palomero, T.; Schnell, S.A.; Belver, L.; Wendorff, A.A.; Xu, L.; Castilla-Martín, M.; Liobet-Navós, D.; Cordon-Cardo, C.; et al. A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. *Nat. Med.* 2014, 20, 1130–1137. [CrossRef]

35. King, B.; Trinarchi, T.; Reavie, L.; Xu, L.; Mullenders, J.; Ntziachristos, P.; Aranda-Orgilles, B.; Perez-Garcia, A.; Shi, J.; Vakoc, C.; et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. *Cell* 2013, 153, 1552–1566. [CrossRef] [PubMed]

36. Sharma, V.M.; Calvo, J.A.; Draheim, K.M.; Cunningham, L.A.; Hermance, N.; Beverly, L.; Krishnamoorthy, V.; Bhasin, M.; Capobianco, A.J.; Kelliler, M.A. NOTCH1 contributes to mouse T-cell leukemia by directly expressing c-myc. *Mol. Cell. Biol.* 2006, 26, 8202–8301. [CrossRef] [PubMed]

37. Girardi, T.; Vicente, C.; Coors, J.; De Keersmaecker, K. The genetics and molecular biology of T-ALL. *Blood* 2017, 129, 1113–1123. [CrossRef] [PubMed]

38. Breit, S.; Stanulla, M.; Flohr, T.; Schrappe, M.; Ludwig, W.-D.; Tolle, G.; Hoppich, M.; Muckenthaler, M.U.; Kulozzi, A.E. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. *Blood* 2006, 108, 1151–1157. [CrossRef] [PubMed]

39. Kox, C.; Zimmermann, M.; Stanulla, M.; Leible, S.; Schrappe, M.; Ludwig, W.D.; Koehler, R.; Tolle, G.; Bandapalli, O.R.; Breit, S.; et al. The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. *Leukemia* 2010, 24, 2005–2013. [CrossRef]

40. Trinquand, A.; Tanguy-Schmidt, A.; Ben Abdelali, R.; Lambert, J.; Beldjord, K.; Lenglin, E.; De Gunzburg, N.; Payet-Bornet, D.; Lhermitte, L.; Mossafa, H.; et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenic risk classification of adult T-cell acute lymphoblastic leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia study. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* 2013, 31, 4333–4342. [CrossRef] [PubMed]

41. Neumann, M.; Nosberg, S.; Schlee, C.; Heesch, S.; Schwartz, S.; Gökbüget, N.; Hoelzer, D.; Graf, A.; Krebs, S.; Bartram, I.; et al. Mutational spectrum of adult T-ALL. *Oncotarget* 2014, 6, 2754–2766. [CrossRef]

42. Zenatti, P.P.; Ribeiro, D.; Li, W.; Zuurbier, L.; Silva, M.C.; Paganin, M.; Tritapoe, J.; Hixon, J.A.; Silveira, A.B.; Cardoso, B.A.; et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. *Nat. Genet.* 2011, 43, 932–939. [CrossRef]

43. Cante-Barrett, K.; Uitdehaag, J.C.; Meijerink, J.P. Structural modeling of JAK1 mutations in T-cell acute lymphoblastic leukemia reveals a second contact site between pseudokinase and kinase domains. *Haematologica* 2016, 101, e189–e191. [CrossRef] [PubMed]

44. Sharma, N.D.; Nickl, C.K.; Kang, H.; Ornatskow, W.; Brown, R.; Ness, S.A.; Loh, M.L.; Mullighan, C.G.; Winter, S.S.; Hunger, S.P.; et al. Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia. *Cancer Sci.* 2019, 110, 1931–1946. [CrossRef] [PubMed]

45. Maude, S.L.; Dolai, S.; Delgado-Martin, C.; Vincent, T.; Robbins, A.; Selvanathan, A.; Ryan, T.; Hall, J.; Wood, A.C.; Tasin, S.K.; et al. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. *Blood* 2015, 125, 1759–1767. [CrossRef] [PubMed]

46. Zhang, J.; Ding, L.; Holmfeldt, L.; Wu, G.; Heatley, S.L.; Payne-Turner, D.; Easton, J.; Chen, X.; Wang, J.; Rusch, M.; et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. *Nature* 2012, 481, 157–163. [CrossRef] [PubMed]

47. Carmen, V.; Claire, S.; Michaël, B.; Ellen, G.; Sandrine, D.; Sofie, D.; Idoya, L.; Alannah, E.; Lucy, C.; La Roberta, S.; et al. Targeted sequencing identifies putative associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia. *Haematologica* 2015, 100, 1301–1310. [CrossRef]

48. Van der Meulen, J.; Van Roy, N.; Van Vlierberghe, P.; Speleman, F. The epigenetic landscape of T-cell acute lymphoblastic leukemia. *Int. J. Biochem. Cell Biol.* 2014, 53, 547–557. [CrossRef]

49. Peirs, S.; Van der Meulen, J.; Van de Walle, I.; Taghon, T.; Speleman, F.; Poppe, B.; Van Vlierberghe, P. Epigenetics in T-cell acute lymphoblastic leukemia. *ImmunoL* 2015, 263, 50–67. [CrossRef] [PubMed]

50. De Keersmaecker, K.; Atak, Z.K.; Li, N.; Vicente, C.; Patchett, S.; Girardi, T.; Gianfelici, V.; Geerdens, E.; Clappier, E.; Porcu, M.; et al. Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. *Nat. Genet.* 2013, 45, 186–190. [CrossRef]

51. Graux, C.; Coors, J.; Melotte, C.; Quentmeier, H.; Ferrando, A.; Levine, R.; Vermeesch, J.R.; Stul, M.; Dutta, B.; Boeckx, N.; et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. *Nat. Genet.* 2004, 36, 1084–1089. [CrossRef]

52. De Keersmaecker, K.; Versele, M.; Coors, J.; Superti-Furga, G.; Hantschel, O. Intrinsinc differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases. *Leukemia* 2008, 22, 2208–2216. [CrossRef]

53. Quintás-Cardama, A.; Tong, W.; Manshouri, T.; Vega, F.; Lennon, P.A.; Coors, J.; Gilliland, D.G.; Lee, F.; Cortes, J.; Kantarjian, H.; et al. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. *Leukemia* 2008, 22, 1117–1124. [CrossRef]
75. Neumann, M.; Heesch, S.; Gökbuget, N.; Schwartz, S.; Schlee, C.; Benlaser, O.; Farhadi-Sartangi, N.; Thibaut, J.; Burmeister, T.; Hoelzer, D.; et al. Clinical and molecular characterization of early T-cell precursor leukemia: A high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations. Blood Cancer J. 2012, 2, e55. [CrossRef]

76. Noronha, E.P.; Marques, L.V.C.; Andrade, F.G.; Thuler, L.C.S.; Terra-Granado, E.; Pombo-de-Oliveira, M.S. The Profile of Immunophenotype and Genotype Aberrations in Subsets of Pediatric T-Cell Acute Lymphoblastic Leukemia. Front. Oncol. 2019, 9, 316. [CrossRef] [PubMed]

77. Bond, J.; Marchand, T.; Touzart, A.; Cieslak, A.; Trinquand, A.; Sutton, L.; Radford-Weiss, I.; Lhermitte, L.; Spicuglia, S.; Dombret, H.; et al. An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: A group for Research in Adult Acute Lymphoblastic Leukemia Study. Haematologica 2016, 101, 732–740. [CrossRef]

78. Conter, V.; Valsecchi, M.G.; Buldini, B.; Parasole, R.; Locatelli, F.; Colombini, A.; Rizzari, C.; Putti, M.C.; Barisone, E.; Lo Nigro, L.; et al. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: A retrospective analysis. Lancet Haematol. 2016, 3, e80–e86. [CrossRef]

79. Bond, J.; Graux, C.; Lhermitte, L.; Lara, D.; Cluzeau, T.; Leguay, T.; Cieslak, A.; Trinquand, A.; Pastoret, C.; Belhocine, M.; et al. Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2017, 35, 2683–2691. [CrossRef] [PubMed]

80. Dunsmore, K.P.; Winter, S.S.; Devidas, M.; Wood, B.L.; Esiashvili, N.; Chen, Z.; Eisenberg, N.; Briegel, N.; Hayashi, R.J.; Gastier-Foster, J.M.; et al. Children’s Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J. Clin. Oncol. 2020, 38, 3282–3293. [CrossRef]

81. Raetz, E.A.; Teachey, D.T. T-cell acute lymphoblastic leukaemia. Hematology 2016, 2016, 580–588. [CrossRef] [PubMed]

82. Vora, A.; Goulden, N.; Wade, R.; Mitchell, C.; Hancock, J.; Hough, R.; Rowntree, C.; Richards, S. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): A randomised controlled trial. Lancet Oncol. 2013, 14, 199–209. [CrossRef]

83. Vega-García, N.; Perez-Jaume, S.; Esperanza-Cebollada, E.; Vicente-Garcés, C.; Torrebadell, M.; Jiménez-Velasco, A.; Ortega, M.; Llop, M.; Abad, L.; Vagace, J.M.; et al. Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on Treatment. Front. Pediatr. 2020, 8, 614521. [CrossRef] [PubMed]

84. Flohr, T.; Schrauder, A.; Cazzaniga, G.; Panzer-Grümayer, R.; van der Velden, V.; Fischer, S.; Stanulla, M.; Niggli, F.K.; Schäfer, B.W.; et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008, 22, 771–782. [CrossRef] [PubMed]

85. Modvig, S.; Madsen, H.O.; Siitonen, S.M.; Rosthøj, S.; Tierens, A.; Juvonenv, V.; Oesnes, L.T.N.; Valerhaugen, H.; Hultdin, M.; Thörn, I.; et al. Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukaemia. Leukemia 2019, 33, 1324–1336. [CrossRef]

86. Schrappe, M.; Valsecchi, M.G.; Bartram, C.R.; Schrauder, A.; Panzer-Grümayer, R.; Möricke, A.; Parasole, R.; Zimmermann, M.; Dworzak, M.; Buldini, B.; et al. Late MRD response determines relapse risk overall and in subsets of childhood T-ALL: Results of the AIEOP-BFM-ALL 2000 study. Blood 2011, 118, 2077–2084. [CrossRef]

87. Vora, A.; Goulend, N.; Mitchell, C.; Hancock, J.; Hough, R.; Rowntree, C.; Moorman, A.V.; Wade, R. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukemia (UKALL 2003): A randomised controlled trial. Lancet Oncol. 2014, 15, 809–818. [CrossRef]

88. Pui, C.H.; Bei, D.; Raimondi, S.C.; Coustan-Smith, E.; Jeha, S.; Cheng, C.; Bowman, W.P.; Sandlund, J.T.; Ribeiro, R.C.; Rubnitz, J.E.; et al. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy. Leukemia 2017, 31, 333–339. [CrossRef]

89. Parekh, C.; Gaynon, P.S.; Abdel-Azim, H. End of induction minimal residual disease alone is not a useful determinant for risk stratification in pediatric T-cell acute lymphoblastic leukemia. Pediatr. Blood Cancer 2015, 62, 2040–2043. [CrossRef]

90. Stock, W.; La, M.; Sanford, B.; Bloomfield, C.D.; Vardiman, J.W.; Gaynon, P.; Larson, R.A.; Nachman, J. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies. Blood 2008, 112, 1646–1654. [CrossRef] [PubMed]

91. Schrappe, M.; Reiter, A.; Zimmermann, M.; Harbott, J.; Ludwig, W.D.; Henze, G.; Gadner, H.; Odenwald, E.; Riehm, H. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia 2000, 14, 2205–2222. [CrossRef]

92. Silverman, L.B.; Declercq, L.; Gelber, R.D.; Dalton, V.K.; Asselin, B.L.; Barr, R.D.; Clavell, L.A.; Hurwitz, C.A.; Moghrabi, A.; Samson, Y.; et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981–1995). Leukemia 2000, 14, 2247–2256. [CrossRef]
112. Rowe, J.M.; Buck, G.; Burnett, A.K.; Chopra, R.; Wiernik, P.H.; Richards, S.M.; Lazarus, H.M.; Franklin, I.M.; Litzow, M.R.; Ciobanu, N.; et al. Induction therapy for adults with acute lymphoblastic leukemia: Results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. *Blood* **2008**, *106*, 3760–3767. [CrossRef]

113. Marks, D.I.; Paietta, E.M.; Moorman, A.V.; Richards, S.M.; Buck, G.; DeWald, G.; Ferrando, A.; Fielding, A.K.; Goldstone, A.H.; Ketterling, R.P.; et al. T-cell acute lymphoblastic leukemia in adults: Clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). *Blood* **2009**, *114*, 5136–5145. [CrossRef] [PubMed]

114. Huguet, F.; Leguay, T.; Raffoux, E.; Thomas, X.; Beldjord, K.; Delabesse, E.; Chevallier, P.; Buzyn, A.; Delannoy, A.; Chalandon, Y.; et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: The GRAALL-2003 study. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **2009**, *27*, 911–918. [CrossRef] [PubMed]

115. Ribera, J.M.; Oriol, A.; Sanz, M.A.; Tormo, M.; Fernández-Abellán, P.; del Puto, E.; Abella, E.; Bueno, J.; Parody, R.; Bastida, P.; et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **2008**, *26*, 1843–1849. [CrossRef] [PubMed]

116. Al-Khabori, M.; Minden, M.D.; Yee, K.W.; Gupta, V.; Schimmer, A.D.; Schuh, A.C.; Xu, W.; Brandwein, J.M. Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic leukemia. *Leuk. Lymphoma* **2010**, *51*, 61–65. [CrossRef]

117. Ben Abdelali, R.; Asnafi, V.; Leguay, T.; Boissel, N.; Buzyn, A.; Chevallier, P.; Thomas, X.; Lepretre, S.; Huguet, F.; Vey, N.; et al. Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: A GRAALL study. *Blood* **2011**, *118*, 5099–5107. [CrossRef]

118. Siegel, S.E.; Stock, W.; Johnson, R.H.; Advani, A.; Muffy, L.; Dourer, D.; Reed, D.; Lewis, M.; Freyer, D.R.; Shah, B.; et al. Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review. *JAMA Oncol.* **2018**, *4*, 725–734. [CrossRef] [PubMed]

119. Goekbuget, N.; Beck, J.; Brueggemann, M.; Burmeister, T.; Buss, E.C.; Frickhofen, N.; Hauft, A.; Morgen, A.; Reichle, A.; Winkler, C.; et al. Moderate Intensive Chemotherapy Including CNS-Prophylaxis with Liposomal Cytarabine Is Feasible and effective in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Trial From the German Multicenter Study Group for Adult ALL (GAML). *Blood* **2012**, *120*, 1493. [CrossRef]

120. Abaza, Y.M.; Kantarjian, H.; Faderl, S.; Jabbour, E.; Jain, N.; Thomas, D.; Kadia, T.; Borthakur, G.; Khoury, J.D.; Burger, J.; et al. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. *Am. J. Hematol.* **2018**, *93*, 91–99. [CrossRef]

121. Kozłowski, P.; Åström, M.; Ahlberg, L.; Bernet, P.; Hulegårdh, E.; Häggland, H.; Karlsson, K.; Markuszewska-Kuczyńska, A.; Tomaszewskatoporska, B.; Smeydmyr, B.; et al. High relapse rate of T cell acute lymphoblastic leukemia in first and second complete remission. *Br. J. Haematol.* **2012**, *160*, 276–287. [CrossRef]

122. Kota, V.K.; Hathaway, A.R.; Shah, B.D.; Peker, D.; Zhang, L.; Jaye, D.L.; Arellano, M.; Khoury, H.J.; Jillella, A.P.; Winton, E.F.; et al. Poor Outcomes with Hyper CVAD Induction for T-Cell Lymphoblastic Leukemia/Lymphoma. *Blood* **2015**, *126*, 3762. [CrossRef]

123. Pidala, J.; Djulbegovic, B.; Anasetti, C.; Kharfan-Dabaja, M.; Kumar, A. Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission. *Cochrane Database Syst. Rev.* **2011**, *11*, Cd008818. [CrossRef]

124. Bakr, M.; Rasheed, W.; Mohamed, S.Y.; Al-Mohareb, F.; Chaudhri, N.; Al-Sharif, F.; Al-Zahrani, H.; Al-Dawsari, G.; Saleh, A.J.; Nassar, A.; et al. Allogeneic hematopoietic stem cell transplantation in adolescent and adult patients with high-risk T cell acute lymphoblastic leukemia. *Biol. Blood Marrow Transplant.* **2012**, *18*, 1897–1904. [CrossRef]

125. Marks, D.I.; Wang, T.; Perez, W.S.; Antin, J.H.; Copelan, E.; Gale, R.P.; George, B.; Gupta, V.; Halter, J.; Khoury, H.J.; et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. *Blood* **2010**, *116*, 366–374. [CrossRef]

126. Reismüller, B.; Attarbaschi, A.; Peters, C.; Dvorzak, M.N.; Pötschger, U.; Urban, C.; Fink, F.M.; Meister, B.; Schmitt, K.; Dieckmann, K.; et al. Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukemia in Austria—A population-based report of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group. *Br. J. Haematol.* **2009**, *144*, 559–570. [CrossRef] [PubMed]

127. Einsiedel, H.G.; von Stackelberg, A.; Hartmann, R.; Fengler, R.; Schrappe, M.; Janka-Schaub, G.; Mann, G.; Hählen, K.; Göbel, U.; Klingebiel, T.; et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: Results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **2005**, *23*, 7942–7950. [CrossRef]

128. Thomas, D.A.; Kantarjian, H.; Smith, T.L.; Koller, C.; Cortes, J.; O’Brien, S.; Giles, F.J.; Gajewski, J.; Pierce, S.; Keating, M.J. Primary refractory and relapsed adult acute lymphoblastic leukemia: Characteristics, treatment results, and prognosis with salvage therapy. *Cancer* **1999**, *86*, 1216–1230. [CrossRef]

129. Hunger, S.P.; Raetz, E.A. How I treat relapsed acute lymphoblastic leukemia in the pediatric population. *Blood* **2020**, *136*, 1803–1812. [CrossRef]

130. Parker, C.; Waters, R.; Leighton, C.; Hancock, J.; Sutton, R.; Moorman, A.V.; Ancliff, P.; Morgan, M.; Masurekar, A.; Goulden, N.; et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukemia (ALL R3): An open-label randomised trial. *Lancet* **2010**, *376*, 2009–2017. [CrossRef]
131. Pullarkat, V.A.; Lacayo, N.J.; Jabbour, E.; Rubnitz, J.E.; Bajel, A.; Laetsch, T.W.; Leonard, J.; Colace, S.I.; Khaw, S.L.; Fleming, S.A.; et al. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. *Cancer Discov.* 2021, 11, 1440–1453. [CrossRef]

132. Zappone, E.; Cencini, E.; Defina, M.; Sicuranza, A.; Gozzetti, A.; Ciofini, S.; Raspadori, D.; Mecacci, B.; Bocchia, M. Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T-cell lymphoblastic leukemia. *Clin. Case Rep.* 2020, 8, 2000–2002. [CrossRef]

133. Kong, J.; Chen, N.; Li, M.; Zhang, J.; Wu, X.; Zong, L.; Wu, D.; Song, B.; Qiu, H. Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia. *Ann. Hematol.* 2021. [CrossRef] [PubMed]

134. Numan, Y.; Alfayez, M.; Maiti, A.; Alvarado, Y.; Jabbour, E.J.; Ferrajoli, A.; Konoplev, S.N.; Kantarjian, H.M.; Bose, P. First report of clinical response to Venetoclax in Early T-cell Precursor Acute Lymphoblastic Leukemia. *JCO Precis. Oncol.* 2018, 2. [CrossRef] [PubMed]

135. La Starza, R.; Cambò, B.; Pierini, A.; Bornhauser, B.; Montanaro, A.; Bourquin, J.P.; Mecucci, C.; Roti, G. Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Lymphoblastic Leukemia. *JCO Precis. Oncol.* 2019, 3. [CrossRef]

136. Horton, T.M.; Whitlock, J.A.; Lu, X.; O’Brien, M.M.; Borowitz, M.J.; Devidas, M.; Raetz, E.A.; Brown, P.A.; Carroll, W.L.; Hunger, S.P. Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: A report from the Children’s Oncology Group. *Br. J. Haematol.* 2019, 186, 274–285. [CrossRef]

137. Lokhorst, H.M.; Plesner, T.; Laubach, J.P.; Nahi, H.; Gimsing, P.; Hansson, M.; Minnema, M.C.; Lassen, U.; Krejcik, J.; Palumbo, A.; et al. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. *N. Engl. J. Med.* 2015, 373, 1207–1219. [CrossRef]

138. Attal, M.; Richardson, P.G.; Rajkumar, S.V.; San-Miguel, J.; Beksac, M.; Spicka, I.; Leleu, X.; Schjesvold, F.; Moreau, P.; Dimopoulos, M.A.; et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study. *Lancet* 2019, 394, 2096–2107. [CrossRef]

139. Deenik, W.; Beverloo, H.B.; van der Poel-van de Luytgaarde, S.C.P.A.M.; Wattel, M.M.; van Esser, J.W.; Valk, P.J.; Cornelissen, J.J. Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia. *Leukemia* 2009, 23, 627–629. [CrossRef]

140. Crombet, O.; Lastrapes, K.; Zieske, A.; Morales-Arias, J. Complete morphologic and molecular remission after introduction of dasatinib in the treatment of a pediatric patient with t-cell acute lymphoblastic leukemia and ABL1 amplification. *Pediatr. Blood Cancer* 2012, 59, 333–334. [CrossRef] [PubMed]

141. Chen, Y.; Zhang, L.; Huang, J.; Hong, X.; Zhao, J.; Wang, Z.; Zhang, K. Dasatinib and chemotherapy in a patient with early T-cell precursor acute lymphoblastic leukemia and NUP214-ABL1 fusion: A case report. *Exp. Ther. Med.* 2017, 14, 3979–3984. [CrossRef]

142. Sawai, C.M.; Freund, J.; Oh, P.; Ndiaye-Lobry, D.; Bretz, J.C.; Strikoudis, A.; Genesca, L.; Trimarchi, T.; Kelliher, M.A.; Clark, M.; et al. Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia. *Cancer Cell* 2012, 22, 452–465. [CrossRef]

143. Raetz, E.A.; Teachey, D.T.; Minard, C.; Liu, X.; Norris, R.; Reid, J.; Beeles, T.; Gore, L.; Fox, E.; Loh, M.L.; et al. Safety of Palbociclib in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoma: A Children’s Oncology Group Pilot Study. *Blood* 2020, 136, 20–21. [CrossRef]

144. Zhang, M.; Yang, L.; Fu, X.; Zhang, L.; Meng, H.; Li, L.; Li, X.; Wang, X.; Sun, Z.; Yu, H.; et al. First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma. *J. Clin. Oncol.* 2020, 38, 3026. [CrossRef]

145. Tasian, S.K.; Teachey, D.T.; Rheingold, S.R. Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies. *Front. Oncol.* 2014, 4, 108. [CrossRef] [PubMed]